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Key Points
• There is currently no
clear consensus on the
best approach to the
management of
patients with APS and
arterial thrombosis.
•Combined antiplatelet
and anticoagulant
therapy may decrease
risk of thrombosis
recurrence in patients
with APS and arterial
thrombosis.
Management for patients with antiphospholipid syndrome (APS) and arterial thrombosis is
controversial. There are no prospective data demonstrating the superiority of high- or
moderate-intensity anticoagulation with vitamin K antagonists over antiplatelet agents.
Using 2 antiphospholipid antibodydatabases (single center [NewYork PresbyterianHospital]
and multicenter [Antiphospholipid Syndrome Alliance for Clinical Trials and International
Networking]), we retrospectively collected demographic and clinical data of patients with
APS and arterial thrombosis. The primary outcome was recurrent thrombosis rate after
initial arterial thrombosis in patientswith APS treatedwith antiplatelet and/or anticoagulant
therapy. We identified 139 patients with a median follow-up time of 4.24 years after initial
thrombosis. Thirty-seven patients (27.3%) received anticoagulants, 43 (30.9%) antiplatelets,
and58 (41.7%) combined therapy. Sixteenpatients (37.2%) in the antiplatelet group, 9 (23.7%)
in the anticoagulant group, and 4 (6.9%) in the combined therapy group experienced
recurrent thrombosis. We estimate that 20% of patients will experience a recurrence by 3.4,
7.3, and 16.3 years, respectively, depending on assignment to antiplatelet, anticoagulant, or
combined therapy. These results suggest that combined therapy decreases the rate of and
increases the time to thrombosis recurrence in patients with APS presenting with arterial
thrombosis.
Introduction
Antiphospholipid syndrome (APS) is characterized by vascular thrombosis and/or pregnancy morbidity
in patients with persistently positive antiphospholipid (aPL) antibodies.1,2 Management for patients with
APS presenting with arterial thrombosis remains controversial, with no prospective data demonstrating
the superiority of high- or moderate-intensity anticoagulation with vitamin K antagonists (VKAs) over
antiplatelet agents.3-7 The Antiphospholipid Antibodies and Stroke Study (APASS) showed that a
positive lupus anticoagulant (LA) or anticardiolipin antibodies (aCL) antibody among patients with
ischemic stroke did not predict either increased risk for subsequent vascular occlusive events over 2
years or a distinct response to aspirin or VKAs.8 Another study evaluated the effect of treatments for
secondary thromboprophylaxis in 20 patients presenting with a stroke, suggesting that a combination of
antiplatelet and anticoagulant agents may be superior to antiplatelets alone.9 We sought to determine
the rate of recurrent thrombosis after initial arterial thrombosis in patients with APS treated with
antiplatelet and/or anticoagulant therapy.
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Methods
Using 2 aPL antibody databases (single center [New York Presbyterian
Hospital (NYPH) from January 2006 to June 2016] and multicenter
[Antiphospholipid Syndrome Alliance for Clinical Trials and International
Networking (APS ACTION) from August 2012 to June 2016]),10 we
retrospectively analyzed demographic and clinical data of patients with
APS who presented with arterial thrombosis. Data included sex, age,
ethnicity, number of cardiovascular (CV) risk factors (including
hypertension, smoking, hyperlipidemia, diabetes, and family history of
early CV disease), type of aPL antibody, concomitant autoimmune
disorders, and treatment modalities (antiplatelet and/or anticoagulant).
Patients were observed until first recurrent thrombosis (arterial, venous,
or microvascular) or last clinic or registry visit. Baseline measures across
treatment groups were compared using x2 and Kruskal-Wallis tests for
categorical and continuous variables, respectively. Kaplan-Meier curves
with log-rank tests as well as Cox proportional hazards regression were
used to examine the primary outcomes of this study: rate of and time to
recurrent thrombosis. Therapies were determined at the time of start of
treatment and may have changed over time. However, we analyzed
patients according to intention to treat.
Patients were eligible for the study if they were $18 years of age,
had a history of arterial thrombosis, and moderate- to high-titer aPL
enzyme-linked immunosorbent assay (aCL, anti-b2 glycoprotein-1),
immunoglobulin G (IgG), IgM, and IgA isotypes ($40 U/mL), and/or
positive LA test on 2 occasions$ 12 weeks apart as per the updated
Sapporo APS Classification Criteria.11 Triple positivity was defined as
having positive LA, aCL, and anti-b2 glycoprotein-1 antibodies. Arterial
thrombosis was defined as cerebrovascular accident (CVA), transient
ischemic attack (TIA), myocardial infarction, or other acute arterial
thrombosis (renal, splanchnic, peripheral). Additionally, patients had to
be treated with antiplatelet agents (aspirin and/or clopidogrel),
anticoagulants, or both after initial arterial event. Patients who had
presented with venous thrombosis or a combination of arterial and
venous thromboses were excluded. Diagnostic criteria for CVA
included presence of a sudden onset of neurological deficit, with
evidence of new brain injury on computed tomography (CT) or
magnetic resonance imaging. Diagnosis of TIA was defined as the
sudden onset of neurological deficit lasting ,24 hours, without
evidence of brain injury by either CT or brain magnetic resonance
imaging. The definition of acute arterial thrombosis included new onset
of pain or paleness in 1 area of the body, with objective documentation
of occlusion of a blood vessel or infarct on CT scan or angiography.
NYPH database
We reviewed the electronic medical records of all patients with APS.
We recorded 170 patients, 121 of whom were excluded because
they did not meet the inclusion criterion of initial isolated arterial
Table 1. Patient baseline characteristics, recurrence rate, and recurrence by initial site of thrombosis
Characteristic
Therapy, no. (%)
P Overall, no. (%)Anticoagulant Antiplatelet Combined therapy
Overall 38 (27.3) 43 (30.9) 58 (41.7) 139
Median (range) age at first thrombosis, y 37 (22-75) 46 (15-84) 42 (15-65) .011 43 (15-84)
Sex .053
Female 30 (78.9) 23 (53.5) 39 (67.2) 92 (66.2)
Male 8 (21.1) 20 (46.5) 19 (32.8) 47 (33.8)
Ethnicity .188
Asian 3 (7.9) 8 (18.6) 2 (3.4) 13 (9.4)
Black 2 (5.3) 1 (2.3) 3 (5.2) 6 (4.3)
White 22 (57.9) 26 (60.5) 37 (63.8) 85 (61.2)
Middle Eastern 0 (0.0) 1 (2.3) 0 (0.0) 1 (0.7)
Hispanic 7 (18.4) 2 (4.7) 10 (17.2) 19 (13.7)
Not Reported 4 (10.5) 5 (11.6) 6 (10.3) 15 (10.8)
Median (IQR) no. of CV risk factors 2 (1-3.25) 1 (1-2) 1.5 (1.25-1.75) .908 1 (1-2.25)
Location of initial thrombosis .003
Cardiac 2 (5.3) 9 (20.9) 5 (8.6) 16 (11.5)
Cerebral 25 (65.8) 33 (76.7) 43 (74.1) 100 (71.9)
Other* 11 (28.9) 1 (2.3) 10 (17.2) 22 (15.8)
Triple-positive aPL antibodies 12 (31.6) 17 (39.5) 21 (36.2) .757 50 (36.0)
Recurrence observed
Location of initial thrombosis
Cardiac (n 5 16) 1 (50) of 2 2 (22) of 9 0 (0) of 5 3 (20) of 16
Cerebral (n 5 101) 6 (24) of 25 13 (39) of 33 4 (9) of 43 23 (23) of 101
Other* (n 5 22) 2 (18) of 11 1 (100) of 1 0 (0) of 10 3 (14) of 22
All, % 9 16 4 29
IQR, interquartile range.
*Describes initial acute arterial location that did not occur at cerebral or cardiac site.
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thrombosis. Of the 49 remaining patients, 23 were excluded because
of incomplete documentation (resulting from either absence of aPL
antibody confirmatory results or lack of follow-up after initial office
visit). The target international normalized ratio (INR) for patients
receiving VKAs was between 2 and 3. Patient follow-up occurred
every 6 to 12 months at NYPH. In the APS ACTION registry, each
center generally performs follow-up of its patients every 3 to 12
months. Recurrence included any type of thrombosis (arterial,
venous, or microvascular). Documentation of recurrence was based
on clinical history and/or objective documentation by imaging study.
APS ACTION
Individual clinicians from 25 centers around the world contribute
patients to the APS ACTION clinical database and repository
(registry). Retrospective and cross-sectional data are collected at
registry entry. Patients are subsequently followed prospectively
once a year and/or at the time of new aPL antibody–related
thrombosis or pregnancy morbidity. For the purpose of this study,
we used only those data collected at registry entry, which were
based on retrospective follow-up of patients at different centers
every 3 to 12 months. As of December 2016, there were 638
patients enrolled; 138 had presented with arterial thrombosis. Of
these, 25 were excluded because they did not fulfill the eligibility
criteria; a total of 113 patients were included. The target INR was
not recorded in this database. The NYPH institutional review board
approved the study.
Results
There were 139 patients identified; 92 (66.2%) were female
(Table 1). Median age at first thrombotic event was 43 years
(range, 15-84 years). Eighty-five (61.2%) were white, 19 (13.7%)
Hispanic, 13 (9.4%) Asian, 6 (4.3%) black, and 1 (0.7%) Middle
Eastern; the ethnicities of 15 patients (10.8%) were not recorded.
Median follow-up time from initial thrombosis was 4.24 years.
Only 1 patient in the NYPH database had atrial fibrillation. There
were 3 patients receiving dual antiplatelet agents in the NYPH
database and 8 in the APS ACTION registry. Median age at initial
thrombosis significantly differed across treatment groups, at 37, 46,
and 42 for the anticoagulant, antiplatelet, and combined therapy
groups, respectively (P 5 .011). Initial thrombosis was observed
mainly in the cerebrovascular system, with 15 patients presenting
with CVA and 5 with TIA at NYPH and 80 with CVA in the APS
ACTION registry. Patients presenting with cardiac events were
more likely to be treated with antiplatelet agents rather than
anticoagulants or combined therapies (P 5 .002).
Of 139 patients, 48 (34.5%) had an underlying autoimmune
disorder and 50 (36%) had triple-positive aPL antibody. Interest-
ingly, we did not identify any significant differences in outcome
when comparing treatment groups in the presence versus absence
of autoimmune disorders or triple positivity (log rank P 5 .90).
Sixteen patients (37.2%) in the antiplatelet group, 9 (23.7%) in the
anticoagulant group, and 4 (6.9%) in the combined therapy group
experienced recurrent thrombosis during the study period. Of the 29
recurrences, 18 were arterial, 10 were venous, and 1 was a
thrombotic microangiopathy. We estimated that 20% of patients
would experience a recurrent thrombotic event within 7.3 years of
the initial event. Time to thrombotic recurrence varied according
to treatment group (Figure 1; log-rank P , .001), with patients
receiving antiplatelet therapy having the highest risk of recurrence.
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Figure 1. Kaplan-Meier curve of time to recurrent thrombosis by
therapy.
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We estimate that 20% of patients will experience recurrence by 3.4,
7.3, and 16.3 years, respectively, depending on assignment to
antiplatelet, anticoagulant, or combined therapy. Compared with
patients receiving anticoagulants, those receiving antiplatelet agents
had a 2.1-fold increase in hazard of recurrence, although because of
low power, the difference did not demonstrate a statistically
significant trend (95% CI, 0.90-4.7; P 5 .09). Patients receiving
combined therapy had a 70% lower hazard of a recurrent event
(hazard ratio, 0.30; 95% CI, 0.08-0.83; P , .025; Figure 1). These
results did not differ when accounting for age and sex in multivariable
regression. One patient experienced a nonmajor clinically relevant
bleeding event in the NYPH database. There were no documented
deaths in the NPYH registry. In the APS ACTION registry, death was
an exclusion criterion for inclusion in our analysis.
Discussion
Our results differ from those of the APASS trial in that our study
patients who received antiplatelet therapy (aspirin and/or clopidog-
rel) had the highest thrombotic recurrence rate compared with
patients in the APASS trial where the thrombotic recurrence rate
was similar for patients receiving aspirin or warfarin. Furthermore,
our study had a longer median follow-up period of 4.24 years
compared with 2 years in the APASS trial.
The 24% recurrence rate of vascular thrombosis in warfarin-treated
patients in our study is similar to the reported 26% rate in the
Warfarin Aspirin Stroke Study (WARSS).12 However, in the
WARSS study, the target INR range was lower (INR, 1.4-2.8)
than the INR of 2.0 to 3.0 among patients in the NYPH database.
We found a higher rate of thrombotic recurrence (37.2%) in
aspirin-treated patients in our study compared with 22% of aPL
antibody–negative treated patients in the WARSS trial.
The major strength of our study was the ability to evaluate 3 different
therapeutic alternatives (antiplatelet, anticoagulant, or combined
therapy) in patients with APS with arterial thrombosis. The superiority
of combined therapy in the current study highlights the multifactorial
nature of thrombosis in these patients with complex disease. However,
even among those receiving combined therapy, a substantial number
(7%) developed a recurrent event during the study period, indicating
the need for novel therapeutic approaches in this population. The
heterogeneity of thrombotic risk factors complicates both study design
and treatment decisions for patients with APS.13 This heterogeneity
provides a putative explanation for the success of combined therapy in
achieving adequate secondary thromboprophylaxis, because coverage
of a wider range of thrombotic causes may reduce risk of recurrence.
This explanation is 1 of several and requires further evaluation with
prospective multicenter studies. An additional strength of our study
was the inclusion of patients from the APS ACTION registry, which
provides a global representation of patients with APS.
Our study has limitations that may have affected our conclusions.
The retrospective design, the relatively small number of patients and
recurrent events observed, and the inability to evaluate therapy
compliance and INR value at the time of thrombotic events are
some of those limitations. Furthermore, bleeding information was
not available in the APS ACTION registry during data collection for
this study. Additionally, CV risk factors were recorded at the time of
enrollment in the APS ACTION registry (not at time of recurrent
event). Most importantly, therapy was chosen by the treating
physician; thus, different clinical characteristics and recurrence
rates across therapy groups may have resulted from selection bias
and cannot be attributed to the therapy alone. Moreover, the
different recurrence rates in the 3 groups may reflect different
pathophysiology rather than treatment effects. Of the confounders
analyzed, only sex and age differed significantly across groups, with
patients receiving antiplatelet agents more likely to be older and
male; multivariable regression accounting for these factors did not
change conclusions.
In conclusion, our study suggests that combined antiplatelet and
anticoagulant therapy, compared with antiplatelet or anticoagulant
therapy alone, decreases the rate of and increases the time to
thrombosis recurrence in patients with APS presenting with arterial
thrombosis. Randomized controlled trials comparing these regi-
mens will be necessary to confirm our findings.
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